105 related articles for article (PubMed ID: 22307377)
21. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Koopmans N; de Jong IJ; Breeuwsma AJ; van der Veer E
J Urol; 2007 Sep; 178(3 Pt 1):849-53; discussion 853; quiz 1129. PubMed ID: 17631330
[TBL] [Abstract][Full Text] [Related]
22. Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases.
Marin L; Koivula MK; Jukkola-Vuorinen A; Leino A; Risteli J
Ann Clin Biochem; 2011 Sep; 48(Pt 5):447-51. PubMed ID: 21733929
[TBL] [Abstract][Full Text] [Related]
23. Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy.
Lumachi F; Basso SM; Camozzi V; Tozzoli R; Spaziante R; Ermani M
Clin Chim Acta; 2016 Sep; 460():227-30. PubMed ID: 27404457
[TBL] [Abstract][Full Text] [Related]
24. Bone turnover markers and bone scintigraphy in the evaluation of the skeletal metastases.
Chrapko BE; Nocuń A; Gołebiewska R; Jankowska H; Zaorska-Rajca J
Nucl Med Rev Cent East Eur; 2005; 8(2):100-4. PubMed ID: 16437394
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
Urakawa H; Ando Y; Hase T; Kikumori T; Arai E; Maeda O; Mitsuma A; Sugishita M; Shimokata T; Ikuta K; Ishiguro N; Nishida Y
Int J Cancer; 2020 Jun; 146(12):3504-3515. PubMed ID: 31846063
[TBL] [Abstract][Full Text] [Related]
26. PINP as serum marker of metastatic spread to the bone in breast cancer patients.
Lüftner D; Jozereau D; Schildhauer S; Geppert R; Müller C; Fiolka G; Wernecke KD; Possinger K
Anticancer Res; 2005; 25(3A):1491-9. PubMed ID: 16033050
[TBL] [Abstract][Full Text] [Related]
27. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma.
Abildgaard N; Brixen K; Eriksen EF; Kristensen JE; Nielsen JL; Heickendorff L
Haematologica; 2004 May; 89(5):567-77. PubMed ID: 15136220
[TBL] [Abstract][Full Text] [Related]
28. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
Respirology; 2005 Jun; 10(3):300-4. PubMed ID: 15955141
[TBL] [Abstract][Full Text] [Related]
29. The role of biomarkers in the management of bone-homing malignancies.
D'Oronzo S; Brown J; Coleman R
J Bone Oncol; 2017 Nov; 9():1-9. PubMed ID: 28948139
[TBL] [Abstract][Full Text] [Related]
30. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
Igawa T; Sakai H; Kanetake H; Saito Y
Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
[TBL] [Abstract][Full Text] [Related]
31. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
32. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
33. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications.
Terpos E; Kiagia M; Karapanagiotou EM; Charpidou A; Dilana KD; Nasothimiou E; Harrington KJ; Polyzos A; Syrigos KN
Anticancer Res; 2009 May; 29(5):1651-7. PubMed ID: 19443381
[TBL] [Abstract][Full Text] [Related]
34. Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?
Lipton A; Costa L; Coleman RE
Breast Dis; 2011; 33(2):59-69. PubMed ID: 22142664
[TBL] [Abstract][Full Text] [Related]
35. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
36. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
[TBL] [Abstract][Full Text] [Related]
37. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.
Glover SJ; Eastell R; McCloskey EV; Rogers A; Garnero P; Lowery J; Belleli R; Wright TM; John MR
Bone; 2009 Dec; 45(6):1053-8. PubMed ID: 19679211
[TBL] [Abstract][Full Text] [Related]
38. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
[TBL] [Abstract][Full Text] [Related]
39. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
40. Bone-marker levels in patients with prostate cancer: potential correlations with outcomes.
Saad F; Lipton A
Curr Opin Support Palliat Care; 2010 Sep; 4(3):127-34. PubMed ID: 20489645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
